A-share subscription | Yuelong Technology (920188.BJ) opens subscription. Mainly engaged in research and development, production and sales of flexible fluid conveying pipelines.
On March 16th, Joylong Technology (920188.BJ) started its subscription period.
On March 16, Yuelong Technology (920188.BJ) started its subscription with an issue price of 14.04 yuan per share and a subscription limit of 989,600 shares. The price-to-earnings ratio is 14.99 times, and it belongs to the North Exchange. Zhongtai is the sponsoring institution.
According to the prospectus, Yuelong Technology is mainly engaged in the research, development, production, and sales of fluid transmission flexible pipelines, including marine engineering flexible pipelines, land oil and gas flexible pipelines, and industrial special rubber hose products.
The company's core products are different from traditional rubber hoses, focusing on the high-performance market of extreme complex conditions such as ultra-high pressure/high pressure, ultra-low temperature/low temperature, high temperature, corrosion, erosion, etc. The products are customized production based on application conditions and transport media, primarily used in offshore oil and gas drilling and mining equipment, deep-sea mining equipment, onshore oil and gas drilling and mining equipment, large oil and gas reserve fields, as well as engineering machinery, chemical industry, rail transportation, food and other fields.
The company's products are sold globally, with customers in China, Europe, America, Southeast Asia, the Middle East, Africa, and other countries and regions, providing products and supporting services to many large enterprises such as CNOOC, CNPC, Sinopec, China Merchants Heavy Industries, China International Marine Containers, Shanghai Waigaoqiao Free Trade Zone Group, Schlumberger, Terrebourg, National Oilwell Varco (NOV), ExxonMobil, FET, and other large enterprises.
In terms of financials, in 2022, 2023, 2024, and January-June 2025, the company achieved operating income of approximately 189 million yuan, 219 million yuan, 268 million yuan, and 153 million yuan, respectively. The net profit attributable to the parent company's shareholders was approximately 47.9234 million yuan, 60.7817 million yuan, 83.4233 million yuan, and 52.9338 million yuan.
Related Articles

Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.

Don't be scared by panic! The conflict in the Middle East has created a "golden buying opportunity". Are these two high-yield blue-chip stocks worth investing in with your eyes closed?

UBS: HK & CHINA GAS (00003) core operating profit rose 4% last year as expected. Rating "Neutral"
Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.

Don't be scared by panic! The conflict in the Middle East has created a "golden buying opportunity". Are these two high-yield blue-chip stocks worth investing in with your eyes closed?

UBS: HK & CHINA GAS (00003) core operating profit rose 4% last year as expected. Rating "Neutral"






